Bothell biotech firm faces delisting from Nasdaq again

Bothell-based Cocrystal Pharma Inc., a publicly traded company on Nasdaq, received notice last week that it's in danger of being delisted from the stock exchange. The clinical-stage biotech firm has failed to maintain the minimum bid price for its common stock — at least $1 per share — for 30 straight business days, in violation of the market's listing rule, according to a letter sent by Nasdaq. Shares of the stock closed at $0.85 on Wednesday. It last closed above $1 on Sept. 22, when it finished…